Tag: C-reactive protein
Lilly’s oral GLP-1, orforglipron, is successful in third Phase 3 trial
Eli Lilly and Company announced positive topline results from the Phase 3 ATTAIN-2 trial, evaluating orforglipron, an investigational oral GLP-1 receptor agonist, in adults...